Amgen's Sensipar franchise extender succeeds in first Phase III
This article was originally published in Scrip
Executive Summary
Two years after Amgen acquired KAI Pharmaceuticals and its drug for hyperparathyroidism in chronic kidney disease (CKD), the Thousand Oaks, California-based biotechnology company is reporting statistically significant Phase III results for AMG 416 (KAI-4169, velcalcetide), which could be on the market before US patents for Amgen's Sensipar (cinacalcet) expire.